Two Sigma Advisers
FTH

Two Sigma Advisers’s Faeth Therapeutics FTH Stock Holding History

Two Sigma Advisers’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-950
Closed -$19.9K – 2661
2024
Q1 		$19.9K Hold
950
– – ﹤0.01% 2403
2023
Q4 		$13.1K Sell
950
-20
-2% -$273 ﹤0.01% 2462
2023
Q3 		$15.5K Sell
970
-275
-22% -$5.91K ﹤0.01% 2333
2023
Q2 		$28.4K Sell
1,245
-70
-5% -$2.05K ﹤0.01% 2308
2023
Q1 		$39.5K Sell
1,315
-455
-26% -$13.5K ﹤0.01% 2473
2022
Q4 		$52.7K Sell
1,770
-125
-7% -$3.67K ﹤0.01% 2359
2022
Q3 		$59K Sell
1,895
-160
-8% -$6.29K ﹤0.01% 2362
2022
Q2 		$93K Buy
2,055
+10
+0.5% +$375 ﹤0.01% 2397
2022
Q1 		$94K Buy
2,045
+1,045
+105% +$83.2K ﹤0.01% 2516
2021
Q4 		$116K Buy
+1,000
New +$149K ﹤0.01% 2392
2021
Q3 		– Sell
-1,160
Closed -$226K – 2656
2021
Q2 		$226K Buy
1,160
+610
+111% +$151K ﹤0.01% 2238
2021
Q1 		$160K Buy
+550
New +$184K ﹤0.01% 2387

Other funds holding FTH

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Two Sigma Advisers's FTH Position: Q2 2024 in Review

Two Sigma Advisers sold out of Faeth Therapeutics (FTH) in Q2 2024, closing a stake of 950 shares — an estimated $19.9K sold.

Two Sigma Advisers first reported a position in FTH in Q1 2021 and held it in 12 quarters. The position peaked at $226K in Q2 2021. 23 funds tracked by Wall St. Rank hold FTH as of Q2 2024.

  • Two Sigma Advisers reported no remaining Faeth Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 950 Faeth Therapeutics shares in Q2 2024, an estimated $19.9K.
  • Two Sigma Advisers first reported a position in Faeth Therapeutics in Q1 2021 and held it in 12 quarters.
  • Two Sigma Advisers's Faeth Therapeutics position peaked at $226K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2024.

Based on Two Sigma Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.